BridgeBio reported positive top-line results from Propel 3, a global Phase 3 trial of oral infigratinib in children with achondroplasia, meeting its primary endpoint for increased annualized height velocity versus placebo. The company said the drug produced the largest growth signal seen in a randomized trial to date for the condition and plans regulatory submissions later this year. The trial enrolled roughly 110 pediatric patients and showed statistically significant and clinically meaningful improvement in growth rate and body composition; safety was described as manageable with transient, asymptomatic phosphate elevations in a small number of patients. BridgeBio intends to discuss the data with regulators to advance filings in the U.S. and other markets and to pursue additional indications such as hypochondroplasia. The readout tightens competition in achondroplasia, where BioMarin’s injectable therapy is established and Ascendis has a weekly contender under review. An orally administered FGFR3 inhibitor that delivers meaningful growth could reshape treatment choice and payer dynamics in the rare-disease pediatric market.